Table 1.

Fifteen gene-breaking candidates studied in detail

Accession number	Gene name	L1 EST	% id to L1rp	TSD len^b
NM_000245^a	MET	CB988551	97%	13
NM_000740	CHRM3: cholinergic receptor, muscarinic 3	CD654050	98%	6
NM_002499	Neogenin 1	BX951091	96%	8
NM_004411^a	Dynein	AA220950	96%	6
NM_004866^a	SCAMP1	BE566710	96%	5
NM_005816^a	CD96 antigen	BE568884	98%	13
NM_014497	NP220 nuclear protein	BG542212	98%	7
NM_014960	Arylsulfatase G	BG994996	96%	8
NM_017679	Breast carcinoma amplified sequence 3 (BCAS3)	AJ518836	97%	15
NM_022743	SMYD3	BM809976	97%	8
NM_024583^a	Secernin 3	AA226814	97%	6
NM_145259	Activin A receptor	BE787024	98%	9
NM_175624	RAB3A interacting protein (rabin3)	BE617461	99%	11
NM_182758		BX957167	96%	10
NM_198499		CN272126	97%	6

The chimp orthologs of NM_000740, NM_175624, and NM_145259 do not contain an L1 corresponding to the human intronic antisense L1 sequences examined here. TSD, target site duplication.
↵a Indicates examples already found by Nigumann et al. (2002).
↵b len = length

Gene-breaking: A new paradigm for human retrotransposon-mediated gene evolution